Zinger Key Points
- CBD of Denver's revenues reached roughly $1.3 million with a split of approximately $1,134,000 for Luxora and roughly $176,000 for Libra 9.
- Luxora's ongoing efforts in the European CBD wholesale market are significantly contributing to growth.
- Get prepared for the Fed’s next move—live with Matt Maley on Wednesday, May 7 at 6 PM ET. Reserve your free spot now.
CBD of Denver, Inc. CBDD reported a strong fourth quarter on Thursday, with revenues reaching roughly $1.310,000 with a split of approximately $1,134,000 for Luxora and approximately $176,000 for Libra 9.
“Despite a challenging economic environment, the increase in revenue confirms that our strategies are driving growth across both verticals," Axel Reinke, CEO of CBD of Denver, said. "With a current order backlog of approximately $150,000 for the Anti-Slip product line, we are confidently entering the new year.”
The Denver-based company attributes its growth to several factors.
In addition to the partnership between EDEKA and the Magic Lappen product driving sales across various regions in Germany, the Libra 9 team’s presence at numerous trade shows is enhancing brand recognition and fostering new partnerships, Reinke continued.
"These partnerships range from wine dealers to specialized car cleaning and detailing companies, and include a teleshopping partnership,” he said.
Meanwhile, Luxora’s ongoing efforts in the European CBD wholesale market are significantly contributing to growth, Jan Schwager, CEO of Luxora, highlighted.
“Despite continued market challenges and consolidation in the CBD industry, there is a strong interest in our products," Schwager said. "Our partnerships in North and South America are crucial in maintaining our competitive edge and expanding our client network as we explore new markets.”
Luxora Solutions is poised to enter the German market, pending final approval of relevant legislation by the German government.
Germany's pivotal vote on legalizing marijuana, initially slated for December, has been postponed until 2024.
CBDD Price Action
CBD of Denver's shares traded 16.6667% higher at $0.0007 per share after the market close on Wednesday.
Related News
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
